Compare Mesoblast Limited (MESO) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Mesoblast Limited trades at $14.25 (market cap $1.75B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.36 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 185× Mesoblast Limited's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| MESO | VEA | |
|---|---|---|
Market Cap | $1.75B | $323.80B |
Volume | 239,027 | 17,001,112 |
Sector | Health | — |
52-Week High | $20.96 | $73.79 |
52-Week Low | $13.19 | $58.90 |
Typical Hold Time | 15 Days | 131 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
VEA trades at $70.21, down 0.07% with bearish technical signals dominating. The ETF shows mixed institutional activity with several firms increasing positions while others reduced exposure. Recent news highlights VEA's competitive advantages including its 0.03% expense ratio and focus on developed markets excluding the U.S. The current technical setup shows oversold conditions with RSI at 28.40 suggesting potential near-term bounce opportunity.
VEA presents a cost-efficient developed markets exposure with strong dividend yield appeal, though technical indicators signal caution. Key risks include global market volatility and currency fluctuations. The ETF's institutional ownership trends and competitive expense ratio support its long-term positioning for investors seeking international diversification beyond U.S. markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
